These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 2428259)

  • 21. Quetiapine and norquetiapine in plasma and cerebrospinal fluid of schizophrenic patients treated with quetiapine: correlations to clinical outcome and HVA, 5-HIAA, and MHPG in CSF.
    Nikisch G; Baumann P; Wiedemann G; Kiessling B; Weisser H; Hertel A; Yoshitake T; Kehr J; Mathé AA
    J Clin Psychopharmacol; 2010 Oct; 30(5):496-503. PubMed ID: 20814316
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Plasma norepinephrine in chronic schizophrenia.
    Breier A; Wolkowitz OM; Roy A; Potter WZ; Pickar D
    Am J Psychiatry; 1990 Nov; 147(11):1467-70. PubMed ID: 2221157
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Electrodermal orienting response and central nervous system dopamine and serotonin activity in schizophrenia.
    Ohlund LS; Lindström LH; Ohman A
    J Nerv Ment Dis; 1992 May; 180(5):304-13. PubMed ID: 1374792
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association between cerebral ventricular enlargement and suicide attempts in chronic schizophrenia.
    Levy AB; Kurtz N; Kling AS
    Am J Psychiatry; 1984 Mar; 141(3):438-9. PubMed ID: 6703115
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Monoamine metabolite levels in cerebrospinal fluid of schizophrenic patients].
    Imazu Y; Kobayashi K; Kawabata M; Shohmori T
    Seishin Shinkeigaku Zasshi; 1985; 87(9):634-42. PubMed ID: 2419935
    [No Abstract]   [Full Text] [Related]  

  • 26. Early death and CSF monoamine metabolites in schizophrenia spectrum psychosis.
    Carlborg A; Jokinen J; Nordström AL; Jönsson EG; Nordström P
    Nord J Psychiatry; 2011 Apr; 65(2):101-5. PubMed ID: 20662686
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Relationship of CSF neurotransmitter metabolite levels to disease severity and disability in multiple sclerosis.
    Markianos M; Koutsis G; Evangelopoulos ME; Mandellos D; Karahalios G; Sfagos C
    J Neurochem; 2009 Jan; 108(1):158-64. PubMed ID: 19014375
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neuroendocrine aspects in monitoring of dopaminergic drugs in man.
    Hietala J; Koulu M; Scheinin M; Syvälahti E
    Methods Find Exp Clin Pharmacol; 1985 Aug; 7(8):451-4. PubMed ID: 3935892
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Birth weight and CT scan findings in chronic schizophrenic patients.
    Mukherjee S; Schnur DB; Reddy R; Decina P
    J Nerv Ment Dis; 1993 Nov; 181(11):672-5. PubMed ID: 8228948
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Brain and CSF volume differences in schizophrenic subtypes.
    Nasrallah HA
    Am J Psychiatry; 1995 May; 152(5):817; author reply 818. PubMed ID: 7726337
    [No Abstract]   [Full Text] [Related]  

  • 31. Schizophrenic patients with deficit syndrome have higher plasma homovanillic acid concentrations and ventricular enlargement.
    Nibuya M; Kanba S; Sekiya U; Suzuki E; Matsuo Y; Kinoshita N; Shintani F; Yagi G; Asai M
    Biol Psychiatry; 1995 Jul; 38(1):50-6. PubMed ID: 7548472
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Asymmetry of the ventricle and age at the onset of schizophrenia.
    Aso M; Kurachi M; Suzuki M; Yuasa S; Matsui M; Saitoh O
    Eur Arch Psychiatry Clin Neurosci; 1995; 245(3):142-4. PubMed ID: 7669820
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A family study of the association of increased ventricular size with schizophrenia.
    DeLisi LE; Goldin LR; Hamovit JR; Maxwell ME; Kurtz D; Gershon ES
    Arch Gen Psychiatry; 1986 Feb; 43(2):148-53. PubMed ID: 3947209
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association of left-handedness with ventricle size and neuropsychological performance in schizophrenia.
    Katsanis J; Iacono WG
    Am J Psychiatry; 1989 Aug; 146(8):1056-8. PubMed ID: 2637683
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of apomorphine infusion on plasma homovanillic acid in normal subjects.
    Davidson M; Kendler KS; Mohs RC; Hollander E; Ryan T; Davis KL
    J Psychiatr Res; 1986; 20(2):131-5. PubMed ID: 3735141
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of growth hormone on brain neurotransmitters.
    Burman P; Hetta J; Karlsson A
    Lancet; 1993 Dec; 342(8885):1492-3. PubMed ID: 7504154
    [No Abstract]   [Full Text] [Related]  

  • 37. Cerebral ventricular enlargement in schizophrenia. A preliminary follow-up study.
    Nasrallah HA; Olson SC; McCalley-Whitters M; Chapman S; Jacoby CG
    Arch Gen Psychiatry; 1986 Feb; 43(2):157-9. PubMed ID: 3947210
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cerebral ventricular size and cognitive impairment in chronic schizophrenia.
    Johnstone EC; Crow TJ; Frith CD; Husband J; Kreel L
    Lancet; 1976 Oct; 2(7992):924-6. PubMed ID: 62160
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Growth hormone levels and lithium ratios as predictors of success of lithium therapy in schizophrenia.
    Hirschowitz J; Zemlan FP; Garver DL
    Am J Psychiatry; 1982 May; 139(5):646-9. PubMed ID: 6803597
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reduced growth hormone response to apomorphine in schizophrenic patients with poor premorbid social functioning.
    Malas KL; van Kammen DP; de Fraites EA; Brown GM; Gold PW
    J Neural Transm; 1987; 69(3-4):319-24. PubMed ID: 3625198
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.